Nervonik, a Los Angeles, CA-based provider of a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system, raised $13M in Series A funding.
The round was led by U.S. Venture Partners (USVP), with participation from Foothill Ventures, Correlation Ventures, and other investors.
The company intends to use the funds to advance its clinical studies, accelerate regulatory clearance, and prepare for commercialization efforts aimed at transforming chronic pain treatment.
Led by Aydin Babakhani, PhD, founder and CEO, Nervonik is a medical device company developing peripheral nerve stimulation (PNS) solutions to treat chronic pain. Leveraging advanced, proprietary, wireless power, and closed-loop sensing technologies, the company is committed to providing minimally invasive, effective, and patient-centric treatment options. Nervonik recently completed its first-in-human clinical study, demonstrating the potential of its PNS technology to transform chronic pain treatment.
FinSMEs
04/03/2025